{"id":9783,"date":"2021-05-14T23:00:00","date_gmt":"2021-05-14T23:00:00","guid":{"rendered":""},"modified":"2021-05-14T23:00:00","modified_gmt":"2021-05-14T23:00:00","slug":"direct-comparison-of-risankizumab-and-fumaric-acid-esters-in-systemic-therapy-naive-patients-with-moderate-to-severe-plaque-psoriasis-a-randomized-controlled-trial","status":"publish","type":"post","link":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2021\/05\/14\/direct-comparison-of-risankizumab-and-fumaric-acid-esters-in-systemic-therapy-naive-patients-with-moderate-to-severe-plaque-psoriasis-a-randomized-controlled-trial\/","title":{"rendered":"Direct Comparison of Risankizumab and Fumaric Acid Esters in Systemic-Therapy-Naive Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial."},"content":{"rendered":"<p>Fumaric acid esters (FAEs; Fumaderm\u00ae ) are the most frequently prescribed first-line systemic treatment for moderate-to-severe plaque psoriasis in Germany. Risankizumab (Skyrizi\u00ae ) is a humanized IgG1 monoclonal antibody that [&#8230;]\n","protected":false},"excerpt":{"rendered":"<p>Fumaric acid esters (FAEs; Fumaderm\u00ae ) are the most frequently prescribed first-line systemic treatment for moderate-to-severe plaque psoriasis in Germany. Risankizumab (Skyrizi\u00ae ) is a humanized IgG1 monoclonal antibody that &#8230;<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[86],"tags":[],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/9783"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=9783"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/9783\/revisions"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=9783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=9783"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=9783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}